a) Schematic representation of how anti-IsdB antibodies were isolated. B cells were first enriched from the peripheral blood mononuclear cells (PBMC) of healthy donors and then sorted by their binding to Pacific-blue® conjugated recombinant IsdB. Individual IgM-CD19+ CD27+ IsdB+ memory B cells were FACS-sorted directly into a 96-well PCR plate. RT-PCR followed by two PCR amplification steps was applied to clone the heavy and light chain BCR variable domain transcripts (VH and VL) of each sorted cell. The amplicons were then sequenced and clustered based on heavy chain variable region gene usages and CDR-H3 sequences. A representative clone from each unique cluster was expressed recombinantly as human IgG for further characterization. b) Detailed gating strategy used to isolate antiIsdB memory B cells. CD3-(T cell), CD16-(monocytes), 7AAD-(viability) and CD19+ (B cell) staining were first used to identify viable B cells and then IgM-CD27+ memory B cells within the total B cell population were selected. Finally, the population of memory B cells which binds Pacific-blue® conjugated IsdB was collected for cloning. Lineage analysis of a single IsdB-reactive antibody cluster from donor D3 revealed continuous sequence permutation of the clone over a 15-month period. Each node stands for a unique VH nucleotide sequence within the clonal cluster and the node size represents the number of duplicate nucleotide sequences within each node (see methods for details on how clones were assigned into nodes). Nodes in the tree topology were organized to infer the path of somatic hypermutations and class-switching undertaken by the `clone based on the obtained sequences, with the least mutated at the top of the tree.
Supplementary Figure 2. Clonal lineage analysis of an IsdB-reactive memory B cell cluster using 454 high throughput sequencing and single cell cloning.
Lineage analysis of a single IsdB-reactive antibody cluster from donor D3 revealed continuous sequence permutation of the clone over a 15-month period. Each node stands for a unique VH nucleotide sequence within the clonal cluster and the node size represents the number of duplicate nucleotide sequences within each node (see methods for details on how clones were assigned into nodes). Nodes in the tree topology were organized to infer the path of somatic hypermutations and class-switching undertaken by the `clone based on the obtained sequences, with the least mutated at the top of the tree.
Supplementary Figure 3. Human serum titers against various S. aureus proteins.
The serum from 65 healthy donors with unspecified S. aureus carrier status was diluted 1:3000 and tested for the presence of antibodies against staphylococcal proteins by ELISA. IsdA, IsdB, IsdC and IsdH belong to the heme-iron acquisition pathway, alpha-toxin and SEB are secreted toxins and human hemoglobin (Hb) was used as negative control. The four donors chosen for single B cell BCR characterization (D1-4) are highlighted in different colors.
Supplementary Figure 6. Antibodies in bin C and P bind IsdB NEAT domains with high affinities.
a-c) Binding characterization of two antibodies in bin P (both IGHV1-69 derived) and a germline-reverted variant against recombinant IsdB NEAT2 domain. d-f) Binding characterization of two antibodies in bin C (IGHV4-39 derived) and a germline-reverted variant against recombinant IsdB. The binding interactions were analyzed using ProteOn XPR36. Briefly, antibodies and their variants were first conjugated on the surfaces of the sensor chip. Serial dilutions of the recombinant proteins at their "nominal" concentrations (shown here; see Methods section) were then injected over the antibody-conjugated surface for binding measurements. The experimental sensorgrams and the global fits are shown for each antibody.
Supplementary Figure 7. Germline reverted antibodies block hemoglobin binding to IsdB.
Recombinant full length IsdB was first allowed to bind germline reverted or control antibodies captured on the Octet sensor chip. The antibody-IsdB complex was then incubated with either hemoglobin or buffer. Lack of hemoglobin binding to the antibody-IsdB complex gives a binding curve similar to the buffer-alone binding curve. Examples of a nonhemoglobin-blocking parental antibody D3-8 (a), a hemoglobin-blocking parental antibody D4-10 (b), and two hemoglobin-blocking germline reverted antibodies, germlined D3-18 (NEAT2) (c ) and germlined D4-10 (NEAT1) (a) are shown. While there is no structure available for the IsdB NEAT1-hemoglobin complex, the interaction can be modeled using the solved structure of methemoglobin bound to IsdH NEAT1. a) The IsdH NEAT1-methemoglobin structure (PDB: 3SZK) shows that residues Y125 and Y126 of α-helix1 of IsdH NEAT1, which are structurally homologous to F164 and Y165 on IsdB NEAT1 α-helix1, are part of the hemoglobin-NEAT binding interface. A previous mutagenesis study also showed that IsdB NEAT 1 variants F164A, Y165A and Y167A completely lost hemoglobin binding 1 . b) The IsdB-antibody structure solved in this study shows that antibody D4-10-N1 targets the same α-helix region on the NEAT domain that is critical for hemoglobin binding.
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Supplementary Figure 14. CDR-H2 aromatic residues of D2-06-N2 (IGHV1-69) and D4-10-N1 (IGHV4-39) protrude into a structurally homologous region on the two respective NEAT domains.
The complex structures of D2-06/NEAT2 and D4-10/NEAT1 were aligned using the NEAT domain as reference. Despite targeting structurally similar NEAT domain folds, IGHV1-69 and IGHV4-39 derived antibodies are highly specific for their respective function-neutralizing epitope on the two NEAT domains. Fine differences in the sidechain identities and structural elements within the complexes likely explain the germline preference for antibody usage in binding the two NEAT domains of IsdB. Serum samples from 32 healthy donors (1-A32), plus those from Donors 1-4, were diluted 1:1000 and tested against recombinant full length IsdB, IsdB NEAT1, IsdB NEAT2 and human hemoglobin (negative control). Testing against IsdB NEAT1 and NEAT2 was also performed in the presence of functional epitope blocking antibodies D4-10 (NEAT1) and D2-06 (NEAT2) in mouse IgG forms, which were confirmed to not interfere with the anti-human IgG detection reagents. All the serum samples exhibited titers against NEAT1 and NEAT2, and their titers were reduced in the presence of blocking antibodies. Results shown are an average of three experiments. Error bars indicate standard deviations. 
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